PTHLH and osteoporosis: Abaloparatide (ABL), an analogue of PTH-related protein (PTHrP (1-34), gene name PTHLH), became the second Food and Drug Administration–approved osteoanabolic for treatment of osteoporosis and has been shown to be somewhat more effective in producing osteoanabolic outcomes compared with teriparatide; ABL resulted in higher bone mineral density in the femurs of osteoporotic, postmenopausal women compared with teriparatide [3, 4, 5].